Novotech recognised as Asia Pacific growth leader by Frost & Sullivan research analysts

You are here

Sydney, Australia: Leading Asia Pacific CRO Novotech has won the Clinical Research Organisation (CRO) Growth Excellence Leadership award in Frost & Sullivan’s Best Practice Awards for 2016. 

In recognising Novotech for the prestigious award, Frost & Sullivan’s Asia Pacific Healthcare Practice Industry Manager Sanjeev Kumar said “Novotech was recognised as a top CRO in Australia and Asia Pacific for excellence in service provision to biopharma clients. The company has exhibited strong growth in a complex environment and now has a physical presence in 11 Asia Pacific countries. It continues to invest in cutting-edge technology, in order to provide a high quality integrated service to its clients… Novotech’s unique focus as an Asia Pacific headquartered midsize CRO ideally complements the growing needs of the biotech community.” 

Recipients of the 2016 Frost & Sullivan Australia Excellence Awards were identified based on an in- depth research conducted by Frost & Sullivan's analysts. The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends. 

Novotech Chief Operating Officer Dr John Moller said: “It is very satisfying to have our commitment to our clients and leadership in the Asia Pacific region recognised. Having our extensive regional footprint allows us to provide clients with immediate customer service and direct access to in-country experts. This allows us to accelerate trial activity and address any country-specific questions as quickly as possible. We look forward to continuing to provide our clients with access to the wealth of clinical trial benefits available in the Asia Pacific region.”